New IMC report shows impact of chronic disease and increased claims on private drug plans
Growth in chronic disease and increased drug claims […]
Growth in chronic disease and increased drug claims […]
We support Health Canada’s decision to delay […]
Ottawa, December 29, 2020 – Innovative Medicines Canada (IMC) issued the following statement today regarding the looming implementation of the Patented Medicines Prices Review Board’s (PMPRB’s) Final Regulations and Guidelines, […]
Ottawa, December 21, 2020—Innovative Medicines Canada (IMC) issued the following statement today warning of the impact the Patented Medicines Prices Review Board’s (PMPRB’s) Final Regulations and Guidelines will have on […]
Ottawa, December 9, 2020 – Innovative Medicines Canada (IMC) issued the following statement today regarding its recent letter to Canada’s First Ministers in advance of their meeting this Thursday with […]
Ottawa, December 2, 2020 – The following statement can be attributed to Declan Hamill, Vice President, Legal, Regulatory Affairs & Compliance, Innovative Medicines Canada in response to the Interim Order Respecting […]
IMC issued the following statement today in response to questions […]
Ottawa, October 23, 2020—Innovative Medicines Canada (IMC) issued the following statement in response to the potential disclosure of proprietary or confidential business information regarding the procurement of COVID-19 medicines and […]
STATEMENT Ottawa, September 25, 2020 – The following statement can be attributed to Declan Hamill, Vice President, Legal, Regulatory Affairs & Compliance, Innovative Medicines Canada in response to the Trump […]
STATEMENT Ottawa, September 23, 2020 – Pamela Fralick, President of Innovative Medicines Canada, issued the following statement in response to today’s Speech from the Throne: “COVID-19 has shown just how […]